Physician profile
Simon K Wu
NPI 1407044241
$2,233.79
in general payments reported to CMS, 2019-2025
15 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $148 · 2021: $124 · 2022: $124 · 2023: $371 · 2024: $244 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.85 | 2019-2025 | Wegovy, Ozempic |
| Glaxosmithkline, LLC. | $513.30 | 2019-2024 | Arexvy |
| Sanofi-Aventis U.S. LLC | $274.02 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $198.04 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.94 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.91 | 2023 | Trulance |
| Renalytix Ai, INC. | $109.09 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Amgen INC. | $73.22 | 2019 | |
| Lilly USA, LLC | $61.15 | 2019-2023 | Mounjaro |
| Janssen Biotech, INC. | $38.83 | 2025 | Tremfya |
| Sanofi Pasteur INC. | $31.55 | 2019-2020 | |
| Pfizer INC. | $28.93 | 2019 | |
| Nabriva Therapeutics, Plc | $17.67 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.75 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.